3-Butan-2-yl-8-methyl-3,8-diazabicyclo[3.2.1]octane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 3-Butan-2-yl-8-methyl-3,8-diazabicyclo[3.2.1]octane
• 英文别名: 3-butan-2-yl-8-methyl-3,8-diazabicyclo[3.2.1]octane
• 化学式: C₁₁H₂₂N₂
• 分子量: 182.31
• InChiKey: DBYJTQASIJDUGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP2389372B1

  公开（公告）日：2015-09-09
• [EN] COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME<br/>[FR] COMPOSÉS ET MÉTHODE DE TRAITEMENT DU SYNDROME DE LIBÉRATION DE CYTOKINE
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2021026451A1

  公开（公告）日：2021-02-11

  Disclosed herein are embodiments of a method for treating or preventing cytokine release syndrome (CRS). In certain embodiments, the method comprises administering a compound, or a salt, solvate, prodrug or pharmaceutical composition thereof, to a subject experiencing, or at risk of developing, CRS. The compound may be a kinase inhibitor, such as a JAK inhibitor and/or an IRAK inhibitor, and/or the compound may have a structure according to Formulas I, III, IV or VII. And the method may comprise administering the compound to a subject who is has received, is currently receiving, and/or will be receiving a cell therapy.